Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 189-199 , May 2007

Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade

  • Rhian M. Touyz, MD, PhD

      Affiliations

    • The Kidney Research Centre, OHRI/University of Ottawa, Ottawa, Ontario, Canada
    • Corresponding Author InformationCorresponding author: Rhian M. Touyz, MD, PhD, Kidney Research Centre, University of Ottawa/Ottawa Health Research Institute, 451 Smyth Road, Room 2513, Ottawa, Ontario, Canada, KIH 8M5. Tel: 613-562-5800; fax: 613-562-5487.
    • ,
  • Carmine Savoia, MD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Ying He, MD

      Affiliations

    • The Kidney Research Centre, OHRI/University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Dierk Endemann, MD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Qian Pu, MD, PhD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Eun A. Ko, MD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Carolina DeCiuceis, MD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Augusto Montezano, PhD

      Affiliations

    • The Kidney Research Centre, OHRI/University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Ernesto L. Schiffrin, MD, PhD

      Affiliations

    • Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada

Received 20 December 2006 ,Accepted 29 January 2007.

References 

  1. Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens. 2003;12:181–187
  2. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403
  3. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice (Evidence for a role in inflammation in angiotensin-induced vascular injury). Arterioscler Thromb Vasc Biol. 2005;25:2106–2113
  4. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8:RA5–RA12
  5. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(21 Suppl 1):II2–II10
  6. Aras R, Sowers JR, Arora R. The proinflammatory and hypercoagulable state of diabetes mellitus. Rev Cardiovasc Med. 2005;6:84–97
  7. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  8. Preston RA, Ledford M, Materson BJ, Baltodano NM, Memon A, Alonso A. Effects of severe, uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor. J Hypertens. 2002;20:871–877
  9. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension. 2002;40:61–66
  10. Malmqvist K, Wallen HN, Held C, Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens. 2002;20:1563–1569
  11. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–2999
  12. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16:429–433
  13. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003;163:93–99
  14. Stumpf C, John S, Jukic J, et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens. 2005;23:995–1000
  15. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens. 2004;17:568–573
  16. Tanaka C, Mannami T, Kamide K, et al. Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res. 2005;28:35–41
  17. Basu S, Larsson A, Vessby J, Vessby B, Berne C. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care. 2005;28:1371–1375
  18. Leinonen ES, Hiukka A, Hurt-Camejo E, et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med. 2004;256:119–127
  19. Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the Cardiovascular Health Study. Am J Kidney Dis. 2004;44:25–34
  20. Alder AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective Observational Study. BMJ. 2000;321:412–419
  21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713
  22. Rosei EA, Rizzoni D, Muiesan ML, et al. CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2005;23:435–444
  23. Sardo MA, Castaldo M, Cinquegrani M, et al. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004;55:195–203
  24. Agabiti Rosei E, Morelli P, Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press Suppl. 2005;1:14–22
  25. Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens. 1999;12:217–222
  26. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905–910
  27. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol. 2003;42:911–913
  28. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol. 2004;16:18–24
  29. Friedman AN, Hunsicker LG, Selhub J, Bostom AG Collaborative Study Group. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int. 2005;68:773–778
  30. Yu HI, Sheu WH, Song YM, Liu HC, Lee WJ, Chen YT. C-reactive protein and risk factors for peripheral vascular disease in subjects with type 2 diabetes mellitus. Diabet Med. 2004;21:336–341
  31. Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006;48:271–277
  32. Hartner A, Veelken R, Wittmann M, Cordasic N, Hilgers KF. Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol. 2005;6:6–8
  33. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 2005;117:152–160
  34. Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetes. 2005;54:2932–2938
  35. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost. 2004;10:133–141
  36. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol. 2004;44:1812–1818
  37. Vilarrasa N, Vendrell J, Maravall J, et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res. 2006;38:507–512
  38. Theuer J, Dechend R, Muller DN, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002;2:3–9
  39. Duncan BB, Schmidt MI, Pankow JS, et al. Atherosclerosis Risk in Communities Study (Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study). Diabetes. 2003;52:1799–1805
  40. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581–587
  41. Sanz-Rosa D, Oubina MP, Cediel E, et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol. 2005;288:H111–H115
  42. Ando H, Jezova M, Zhou J, Saavedra JM. Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann N Y Acad Sci. 2004;1018:345–350
  43. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004;122:339–352
  44. Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications (Emerging new therapeutical strategies). Curr Med Chem. 2005;12:267–275
  45. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond). 2002;103:131–136
  46. Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol. 2002;89:562–566
  47. Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care. 2000;23:1031–1032
  48. Guba M, Steinbauer M, Buchner M, et al. Differential effects of short-term ace- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock. 2000;13:190–196
  49. Held C, Hjemdahl P, Hakan Wallen N, et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris (Results from the APSIS study. The Angina Prognosis Study in Stockholm). Atherosclerosis. 2000;148:179–188
  50. Gomes A, Costa D, Lima JLFC, Fernandes E. Antioxidant activity of β-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?. Bioorg Med Chem. 2006;14:4568–4577
  51. Marfella R, Siniscalchi M, Nappo F, et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens. 2005;18:308–318
  52. Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:133–148
  53. Ridker PM, Danielson E, Rifai N, Glynn RJ Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73–79

 This study was supported by an unrestricted grant from Novartis Pharmaceuticals Canada and by grants 44018 (to RMT) and 13570 (to ELS), as well as by a group grant to the Multidisciplinary Research Group on Hypertension, all from the Canadian Institutes for Health Research. CS and CDeC were supported in part by fellowships from the Italian Society of Hypertension. DHE was supported by a grant from the Deutsche Forschungsgemeinschaft. The authors would like to thank Mireille Kirouac, RN, for devoted follow-up of patients and blood sampling.Conflict of interest: none.

PII: S1933-1711(07)00039-3

doi: 10.1016/j.jash.2007.01.009

Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 189-199 , May 2007

Article Tools

* Image Usage & Resolution